Group

Baseline

p-value^a

After 6 weeks

p-value^b

p-value^a

After 12 weeks

p-value^b

p-value^a

Saliva flow rate

(mL/min)

Placebo

0.95 ± 0.03

0.697

0.97 ± 0.04

>0.050

0.479

0.96 ± 0.03

>0.050

0.223

GK-1

0.97 ± 0.03

1.01 ± 0.03

>0.050

1.01 ± 0.03

>0.050

SIgA concentration

(μg/mL)

Placebo

188.8 ± 20.2

0.367

195.2 ± 18.6

>0.050

0.219

211.4 ± 20.2

>0.050

0.192

GK-1

213.1 ± 17.2

228.5 ± 19.5

>0.050

249.7 ± 21.0

0.010^†

SIgA secretion rate

(μg/min)

Placebo

162.3 ± 11.8

0.057

170.9 ± 11.5

>0.050

0.012*

190.9 ± 15.0

0.015^†

0.027*

GK-1

198.6 ± 15.0

223.0 ± 17.4

>0.050

245.9 ± 19.7

0.005^††

NK-cellactivity

Placebo

59.8 ± 2.4

0.766

62.4 ± 2.4

>0.050

0.680

62.6 ± 2.4

>0.050

0.983

GK-1

58.8 ± 2.7

63.8 ± 2.4

0.002^††

62.6 ± 3.0

0.024^†

selm IFN-γ levels

Placebo

170.7 ± 30.4

0.015*

215.0 ± 42.3

>0.050

0.084

168.5 ± 32.4

>0.050

0.741

GK-1

85.5 ± 15.7

128.3 ± 25.6

>0.050

154.1 ± 28.4

0.007^††